What Happened?
Philadelphia, PA-based Imvax Appointed John Furey as Chief Executive Officer
About the Company
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
About the Person
John Furey is Chief Executive Officer at Imvax. Previously, John held various senior HR leadership roles in the industry.
Info Source
News
Short Profile